Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials

Liang, Shi-Bing; Fang, Min; Liang, Changhao; Lan, Hui-Di; Shen, Chen; Yan, Lijiao; Hu, Xiao-Yang; Han, Mei; Robinson, Nicola; Liu, Jianping

doi:10.1016/j.ctim.2021.102744

Cited by 26 publications

(18 citation statements)

References 21 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this study, a total of 24 SRs were included through the database search ( Figure 1 ). Among the included SRs, TCM medications were evaluated in 21 studies, 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 home-based activity (n=1) 31 and vitamin D (n=2) 32 , 33 were assessed. Various types of TCM medications were included in most of the SRs, and LinghuaQingwen granules or capsules were tested in four SRs ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

“…The overall clinical effectiveness of TCM treatments in relative risk (RR) ranged from 1.15, 95% confidence intervals (CI) [1.04, 1.26] 29 to 1.23, 95% CI [1.04, 1.38] 17 (or odds ratio (OR) 2.5, 95% CI [1.46, 4.29] 15 to 2.67, 95% CI [1.83, 3.89]) 20 , and these differences in summary effect estimates might be introduced from the status of the included RCTs in each SR. TCM herbal medications were reported to show good results in decreasing the rate of disease progression (RR 0.30, 95% CI [0.20, 0.44]) 14 , time to the resolution of fever (standard mean difference (SMD) -0.98, 95% CI [-1.78, -0.17]) 25 and rate of progression to severe COVID-19 cases (RR 0.34, 95% CI [0.18, 0.65]) 27 . Combination therapy with TCM herbal medication and conventional treatments was reported to be effective in the improvement of lung CT for mild to moderate COVID-19 patients.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Complementary and alternative medicine (CAM) interventions for COVID-19: An overview of systematic reviews

Jeon

Kang

Ang

et al. 2022

Integrative Medicine Research

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Complementary and alternative medicine (CAM) interventions for COVID-19: An overview of systematic reviews

Jeon

Kang

Ang

et al. 2022

Integrative Medicine Research

View full text Add to dashboard Cite

“… 53 Several reviews focused only on Chinese herbal medicine. 2 , 3 , 13 , 51 , 56 , 57 , 58 , 59 In this review, we included RCTs from China, India, and Iran which assessed the effect of different herbal formulations in the COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

“…Subsequently, few patent Chinese herbal medicines such as Jinhua Qinggan granules (JHQG), Lianhua Qingwen granules (LHQW), have also been suggested for COVID-19 management. 13 Qingfei Paidu Decoction is another herbal formula used in China to treat patients with COVID-19. Dried Ginger, Hegan Mahuang Decoction and Qingfei Touxie Fuzheng Decoction can effectively treat SARS-CoV-2 as per trial results in China.…”

Section: Introductionmentioning

confidence: 99%

Role of herbal medicines in the management of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

Kumar

Rai

Khan

et al. 2022

Journal of Traditional and Complementary Medicine

View full text Add to dashboard Cite

Background and aim The management of the worldwide spreading COVID-19 consists of amelioration of its symptoms but no cure is yet available. Herbal medicines supplemented with the Western medicine have been applied for COVID-19 treatment in India, China, Iran, and other countries. This systematic review and meta-analysis of RCTs evaluates the effect and safety of herbal intervention in the management of COVID-19. Experimental procedure RCTs from databases like PubMed, Cochrane Library, ScienceDirect, Google Scholar, Science Direct, CTRI, AYUSH Research Portal, India, were reviewed and the data were extracted for study sample demographics, intervention details, clinical effect, inflammatory markers and safety monitoring. Outcomes were expressed as Risk-ratio (RR) with 95% CI for dichotomous data, and Mean-Difference (MD) with 95% CI for continuous data. Result and conclusion From the 32 eligible studies, a total of 3177 COVID-19 patients were included in the review. Herbal intervention as an adjuvant to Western medicine causes significantly higher improvement compared to Western medicine alone [Fever (RR = 1.09 CI 1.03, 1.15), Cough (Risk-Ratio = 1.22 CI 1.08, 1.37), Fatigue (Risk-Ratio = 1.27 CI 1.11, 1.44), Chest CT Improvement (Risk-Ratio = 1.15 CI 1.08, 1.23)]. The laboratory parameters were also better in the herbal medicine group compared to standard care group only WBC (MD = 0.36 CI 0.16, 0.55), Lymphocyte percentage (MD = 5.48 CI 3.05, 7.92), Absolute lymphocyte count (MD = 0.23 CI 0.07, 0.39), CRP (MD = −5.66 CI -7.96, −3.37). However, duration of hospital stays (MD = −1.82 CI -3.84, 0.21); IL-6 (MD = −3.67 CI -8.76, 1.43), ESR Level (MD = −10.38 CI -25.96, 5.21) were statistically insignificant. No significant adverse events for herbal medications were noted in the included RCTs, during the time of the studies. (n = 665, RR 0.93; 95% CI 0.76, 1.14).

show abstract

“…Additionally, traditional Chinese medicine is widely used in the treatment of COVID-19 in China (Liang et al, 2021;Wu and Zhong, 2021). Jingyin granules and Qingfei Paidu decoction, have been recommended for treating the H1N1 influenza A virus infection and COVID-19 in China, and have exhibited an inhibitory effect on CYP1A, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP2C19 and CYP3A (Zhang et al, 2021b;Zhang et al, 2021c).…”

Section: Pharmacological Therapy For Comorbiditymentioning

confidence: 99%

The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has become a new public health crisis threatening the world. Dysregulated immune responses are the most striking pathophysiological features of patients with severe COVID-19, which can result in multiple-organ failure and death. The cytochrome P450 (CYP) system is the most important drug metabolizing enzyme family, which plays a significant role in the metabolism of endogenous or exogenous substances. Endogenous CYPs participate in the biosynthesis or catabolism of endogenous substances, including steroids, vitamins, eicosanoids, and fatty acids, whilst xenobiotic CYPs are associated with the metabolism of environmental toxins, drugs, and carcinogens. CYP expression and activity are greatly affected by immune response. However, changes in CYP expression and/or function in COVID-19 and their impact on COVID-19 pathophysiology and the metabolism of therapeutic agents in COVID-19, remain unclear. In this analysis, we review current evidence predominantly in the following areas: firstly, the possible changes in CYP expression and/or function in COVID-19; secondly, the effects of CYPs on the metabolism of arachidonic acid, vitamins, and steroid hormones in COVID-19; and thirdly, the effects of CYPs on the metabolism of therapeutic COVID-19 drugs.

show abstract

Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials

Abstract: Graphical abstract

Cited by 26 publications

References 21 publications

Complementary and alternative medicine (CAM) interventions for COVID-19: An overview of systematic reviews

Complementary and alternative medicine (CAM) interventions for COVID-19: An overview of systematic reviews

Role of herbal medicines in the management of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy

Contact Info

Product

Resources

About